Elkedonia SAS raised €11 million in a seed round to support clinical development of its first-in-class ELK-1 inhibitor for refractory depression, targeting neuroplasticity pathways. This funding accelerates innovative treatment options in neuropsychiatric disease, highlighting investor confidence in Elkedonia’s novel approach.